According to filings with the U.S. Securities and Exchange Commission, Phenomix Sciences is raising $5,028,735.00 in new funding. Sources indicate that as part of senior management Chief Operating Officer, Ross Higgins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Phenomix Sciences
Phenomix Sciences is a precision medicine obesity biotechnology pioneer on a mission to conquer obesity globally through the science of phenotyping, the understanding of how genes combined with environmental and behavioral factors can inform obesity treatment plans. Mayo Clinic physicians, scientists, and researchers, Drs. Acosta and Camilleri, founded the company under the belief that the key to understanding obesity is unprecedented access to its clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients.

To learn more about Phenomix Sciences, visit http://phenomixsciences.com/

Contact:
Ross Higgins, Chief Operating Officer
877-673-0981
https://www.linkedin.com/in/ross-higgins-103a8338/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.